We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
323 result(s) found, displaying 91 to 100
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SAPHNELO anifrolumab 300 mg concentrated injection vial.
-
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ENHERTU trastuzumab deruxtecan 100 mg powder for injection vial.
-
Prescription medicine registrationActive ingredients: trastuzumab deruxtecan.
-
Australian public assessment report (AusPar)AusPAR for Evusheld (tixagevimab and cilgavimab) for treatment of adults with COVID-19.
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
Prescription medicine decision summaryEvusheld (tixagevimab and cilgavimab) is approved to treat COVID-19
-
Australian public assessment report (AusPar)AusPAR for SAPHNELO (anifrolumab) as add on treatment of adult patients with moderate to severe, active systemic lupus erythematosus.